Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling

Yin,Haitao; Zhou,Yun; Wen,Cuixia; Zhou,Chong; Zhang,Wei; Hu,Xiang; Wang,Lifeng; You,Chuanwen; Shao,Junfei

doi:10.3892/or.2014.3342

Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling

Authors:
- Haitao Yin
- Yun Zhou
- Cuixia Wen
- Chong Zhou
- Wei Zhang
- Xiang Hu
- Lifeng Wang
- Chuanwen You
- Junfei Shao
View Affiliations

Affiliations: Department of Radiotherapy, The Central Hospital of Xuzhou, Affiliated Hospital of Southeast University, Xuzhou, Jiangsu, P.R. China, Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, P.R. China, Department of Oncology, Suqian People's Hospital, Suqian, Jiangsu, P.R. China, Department of Neurosurgery, Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, P.R. China
Published online on: July 18, 2014 https://doi.org/10.3892/or.2014.3342
Pages: 1610-1616

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Temozolomide (TMZ), a DNA alkylating agent, represents the most important chemotherapeutic option for the treatment of glioblastoma in the clinic. Despite its frequent use, the therapeutic efficacy of TMZ remains very limited due to its frequent resistance in glioblastoma. Previous evidence suggested that curcumin (CUM), an ingredient of the Indian spice turmeric, is able to sensitize glioblastoma to TMZ treatment. However, the underlying molecular mechanism remains elusive. In the present study, we performed in vitro and in vivo experiments to evaluate the interaction of CUM and TMZ on the inhibition of glioblastoma and to investigate its potential mechanisms of action using U87MG cell lines and xenograft mouse models. We demonstrated that CUM enhanced the therapeutic response to TMZ in U87MG glioblastoma by enhancing apoptosis. We then proceeded to investigate the potential apoptotic signaling pathways that are involved. We observed a synergistic effect of the combination of CUM and TMZ in generating reactive oxygen species (ROS) production, suggesting that ROS may contribute to the impact of CUM on sensitizing TMZ treatment. We also showed that CUM and TMZ treatment alone significantly suppressed phosphorylated AKT and mTOR, whereas their combination achieved a more pronounced inhibitory effect. These data indicated that blockage of AKT/mTOR signaling appeared to contribute to the elevated apoptosis caused by the combination treatment with CUM and TMZ. In conclusion, this study provided molecular insights into the effects of CUM on the therapeutic response of glioblastoma to TMZ and opened new avenues for optimizing the therapeutic effects of TMZ-based therapies.

View Figures

View References

1	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
2	DeAngelis LM: Brain tumors. N Engl J Med. 344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
3	Laws ER, Parney IF, Huang W, et al: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 99:467–473. 2003. View Article : Google Scholar : PubMed/NCBI
4	Kapoor R, Revesz T and Powell M: Solitary cervical lymphoma presenting as a neurofibroma. Br J Neurosurg. 6:583–586. 1992. View Article : Google Scholar : PubMed/NCBI
5	Perry JR, Bélanger K, Mason WP, et al: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 28:2051–2057. 2010. View Article : Google Scholar : PubMed/NCBI
6	Mirimanoff RO, Gorlia T, Mason W, et al: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 24:2563–2569. 2006. View Article : Google Scholar : PubMed/NCBI
7	Mrugala MM and Chamberlain MC: Mechanisms of disease: temozolomide and glioblastoma - look to the future. Nat Clin Pract Oncol. 5:476–486. 2008. View Article : Google Scholar : PubMed/NCBI
8	Kohsaka S, Wang L, Yachi K, et al: STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther. 11:1289–1299. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kohsaka S, Takahashi K, Wang L, et al: Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Cancer Lett. 331:68–75. 2013. View Article : Google Scholar : PubMed/NCBI
10	Joe B, Vijaykumar M and Lokesh BR: Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 44:97–111. 2004. View Article : Google Scholar : PubMed/NCBI
11	Maheshwari RK, Singh AK, Gaddipati J and Srimal RC: Multiple biological activities of curcumin: a short review. Life Sci. 78:2081–2087. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar
13	Das T, Sa G, Saha B and Das K: Multifocal signal modulation therapy of cancer: ancient weapon, modern targets. Mol Cell Biochem. 336:85–95. 2010. View Article : Google Scholar : PubMed/NCBI
14	Basile V, Ferrari E, Lazzari S, Belluti S, Pignedoli F and Imbriano C: Curcumin derivatives: molecular basis of their anticancer activity. Biochem Pharmacol. 78:1305–1315. 2009. View Article : Google Scholar : PubMed/NCBI
15	Hussain AR, Al-Rasheed M, Manogaran PS, et al: Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias. Apoptosis. 11:245–254. 2006.PubMed/NCBI
16	Zheng S and Chen A: Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J. 384:149–157. 2004. View Article : Google Scholar
17	Lu JJ, Cai YJ and Ding J: The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. Mol Cell Biochem. 360:253–260. 2012. View Article : Google Scholar
18	Ramachandran C, Nair SM, Escalon E and Melnick SJ: Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force in brain tumor cell lines. J Complement Integr Med. 9:Article 20. 2012. View Article : Google Scholar : PubMed/NCBI
19	Chen CC, Taniguchi T and D’Andrea A: The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med. 85:497–509. 2007. View Article : Google Scholar : PubMed/NCBI
20	Roos WP, Batista LF, Naumann SC, et al: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O⁶-methylguanine. Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
21	Lin CJ, Lee CC, Shih YL, et al: Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 52:377–391. 2012. View Article : Google Scholar : PubMed/NCBI
22	Sánchez Y, Simón GP, Calviño E, de Blas E and Aller P: Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines. J Pharmacol Exp Ther. 335:114–123. 2010.
23	Hirose Y, Katayama M, Mirzoeva OK, Berger MS and Pieper RO: Akt activation suppresses Chk2-mediated, methylating agent-induced G₂ arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 65:4861–4869. 2005. View Article : Google Scholar : PubMed/NCBI
24	Chen L, Han L, Shi Z, et al: LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. Mol Med Rep. 5:575–579. 2012.PubMed/NCBI
25	Yu S, Shen G, Khor TO, Kim JH and Kong AN: Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther. 7:2609–2620. 2008. View Article : Google Scholar : PubMed/NCBI
26	Datta SR, Dudek H, Tao X, et al: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
27	Zhang J, Stevens MF and Bradshaw TD: Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
28	Gupta SC, Patchva S, Koh W and Aggarwal BB: Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 39:283–299. 2012. View Article : Google Scholar : PubMed/NCBI
29	Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar